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Abstract 
Multiple Sclerosis (MS) is a central nervous system (CNS) chronic inflammatory 
demyelinating disease leading to various neurological disabilities. The disorder is more 
prevalent for women with a ratio of 3:2 female to male. Objectives: To investigate variation 
within the estrogen receptor 1 (ESR1) polymorphism gene in an Australian MS case-control 
population using two intragenic restriction fragment length polymorphisms; the G594A 
located in exon 8 detected with the BtgI restriction enzyme and T938C located in intron 1, 
detected with PvuII. One hundred and ten Australian MS patients were studied, with patients 
classified clinically as Relapsing Remitting MS (RR-MS), Secondary Progressive MS (SP-
MS) or Primary Progressive MS (PP-MS). Also, 110 age, sex and ethnicity matched controls 
were investigated as a comparative group. No significant difference in the allelic distribution 
frequency was found between the case and control groups for the ESR1 PvuII (P = 0.50) and 
Btg1 (P = 0.45) marker. Our results do not support a role for these two ESR1 markers in 
multiple sclerosis susceptibility, however other markers within ESR1 should not be excluded 
for potential involvement in the disorder.  
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1. Introduction 
Multiple Sclerosis (MS) is a chronic, inflammatory, demyelinating disease of the central 
nervous system (CNS) that predominantly affects young Caucasians, usually with an age of 
onset of 18 to 40 years old. Females account for approximately 60% of MS cases [1]. The 
CNS in MS sufferers is affected with patches of myelin degeneration resulting from 
multifocal inflammatory events. Myelin, which is composed of a lipid bilayer and proteins, 
forms the extended membrane of oligodendrocyte and insulates neurons to provide rapid 
conduction of the action potential along the axons. Sex steroid hormones are very important 
in pregnancy and interestingly, within the third trimester of gestation, MS sufferers show a 
remarkable and unexplained decrease in relapses [2]. In addition, estrogens are capable of 
immunomodulation. Estrogen has been shown to increase the expression of the Forkhead box 
P3 (FoxP3), a gene localized to the short arm of chromosome X. FoxP3 binds to the promoter 
of IL2 gene and suppress its expression. Also, FoxP3 suppresses the gene expression of INFg 
and interleukin 4 in naïve T cells [3]. Interestingly, the estrogen dependent Fox P3 has been 
found to be down-expressed in MS peripheral CD4 + CD25+ T cells [4] while estrogen E2 
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(17-beta-estradiol) increases the proliferation of CD4 + CD25+ [5]. Furthermore, in estrogen 
treated and pregnant mice, FoxP3 shows enhanced expression compared to controls [6]. 
Interestingly, estrogen biosynthesis is dependent on vitamin D receptor, a gene in which a 
polymorphism has been previously found to be positively associated with MS [7] and [8]. 
VDR has a direct action on estrogen biosynthesis specifically within the aromatase gene [9]. 
Considering the potential significance of genes relating to estrogen in MS, we decided to 
investigate two polymorphisms in the ESR1 gene (with PvuII in intron 1 region and Btg1 in 
exon 8) for their potential involvement in MS susceptibility in an Australian MS population. 
 
2. Methods 
2.1. Subject groups 
The participants of the study were unrelated and of Caucasian (Northern European) origin. 
The study protocol was approved by Griffith University's ethics committee for 
experimentation on humans. The test groups consisted of 110 MS patients and 110 controls, 
matched for ethnicity, sex and age (+/− 5 years). The MS population was obtained from 
patients from the Multiple Sclerosis Clinic at the Royal Brisbane and Women's Hospital, 
mainly from the South East Queensland region. All MS individuals were diagnosed using the 
2005 revised McDonald criteria for multiple sclerosis [10]. The populations were all 
descendent from northern European parents, grand parents or great grand parents who came 
to Australia within the last 200 years. The population investigated did not contain any native 
Australians (Aboriginal or Torres Straight Island descent). This case group consisted of 75% 
women and 25% men and were subdivided into three groups according to the clinical course: 
Relapsing-Remitting MS (RR-MS), Secondary Progressive MS (SP-MS) and Primary 
Progressive MS (PP-MS) with frequencies of 42%, 37%, and 21% respectively. The control 
group was also obtained from the South East Queensland region through the Genomics 
Research Centre, Southport, with each control matched to an MS patient for the variables age 
(+/− 5 years), sex, and ethnicity. All individuals gave informed consent before participating in 
the research. Genomic DNA was extracted from peripheral blood leucocytes using a standard 
salting-out protocol. 
 
2.2. Genotyping 
Two polymorphisms were genotyped with two restriction fragment length polymorphisms 
(RFLPs) used to detect each variant. Intron 1 of ESR1 was investigated using the PvuII 
restriction enzyme to detect, at the nucleotide position 938, a T to C substitution. The second 
marker Btg1 was used to detect a polymorphism of ESR1 in the 3′ region of the gene 
specifically in Exon 8 to detect an A to G substitution. These polymorphic regions were 
amplified by standard, unlabeled oligonucleotides followed by restriction enzyme digestion 
corresponding to each RFLP. Oligonucleotide primers used for PvuII and Btg1 RFLP were: 
forward primer 5′ TGACACATGTTCTGTGTTGTCC3′; reverse 5′ 
CTGGTGCAGGTAGTATGTTTTT 3′; and for Btg1 RFLP were: forward 5′ 
CTGTGTCTTCCC ACCTACAG 3′ and reverse 5′ CGTGTGGGAGCCAGGGAGCT 3′. For 
detection of the ESR1 intronic marker, 20–30 ng genomic DNA was amplified with 1 X 
polymerase chain reaction (PCR) buffer, 3 mM MgCl2, 0.2 mM each dNTP, 0.2 µM each 
primer and Taq polymerase in a 20-µL final volume on a Corbett (Sydney, Australia) PC-960 
thermocycler. Cycles consisted of a 2-min denaturation at 94 °C followed by 40 cycles of 
94 °C for 1 min and 56 °C for 30 s and 72 °C for 30 s then a final extension at 72 °C for 
2 min. PCR products were digested with PvuII (1 U at 37 °C) and electrophoresed on 5% 
ethidium bromide stained agarose gels. Genotypes were denoted as TT (239 bp), TC (239, 
187, 52 bp) or CC (187, 52 bp). For detection of the Btg1 exonic marker, amplification 
required 20–50 ng genomic DNA with PCR Premix Optimisation Buffer E (Epicentre 
Technologies, Madison, WI), 0.2 µM of each primer and Taq polymerase in a 25-µL reaction 
volume. Amplification was then performed on a Perkin Elmer (Foster City, CA) thermocycler 
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with a 94°C initial denaturation for 2 min followed by 5 cycles of 94°C for 45 s, 68°C for 60 s 
and 72°C for 2 min; and a further 35 cycles of 94°C for 30 s, 67°C for 30 s and 72°C for 45 s 
with an addition of 5 min final extension at 72°C. Following amplification, PCR products 
were digested with Btg1 (2 U at 37°C) and electrophoresed on 2% agarose gels stained with 
ethidium bromide. Genotypes were determined as AA (227 bp), AG (227, 129, 98 bp) or GG 
(129, 98 bp) for the Btg1 polymorphism (an undigested sample indicated the presence of the 
594A allele). 
 
TABLE 1. Distribution of ESR1 PvuII variant (genotype) frequencies in MS case and control groups 
Genotype   MS cases (n=110)a  Control cases (n=110)b 
CC    30 (27.3%)   29 (26.4%) 
CT    55 (50.0%)   50 (45.4%) 
TT    25 (22.7%)   31 (28.2%) 
χ2=0.9; P-value=0.63. 
 
Alleles    MS cases (n=110)  Control cases (n=110) 
C 115 (52.3%) 108(49.1%) 
T 105 (47.7%) 112 (50.9%) 
χ2=0.45; P-value=0.50. 
 
a Hardy–Weinberg equilibrium P=0.98. 
b Hardy–Weinberg equilibrium P=0.34. 
 
2.3. Statistical analysis 
Genotype and allele frequencies for the ESR variants were calculated from observed genotype 
counts. As a statistical control for systematic genotyping error and population stratification, 
the expected genotype proportions according to the Hardy–Weinberg law were calculated and 
compared to observed genotypes. Genotype and allele frequencies were initially assessed for 
association with MS using conventional contingency table analyses incorporating the standard 
chi-squared test for independence. This analysis produces a χ2 statistic with one or two 
degrees of freedom and corresponding P-values for allele and genotype distributions, 
respectively. 
 
TABLE 2. Distribution of ESR1 Btg1 variant (genotype) frequencies in MS case and control groups 
Genotype   MS cases (n=110)a  Control cases (n=110)b 
GG    60 (54.5%)   64 (58.2.9%) 
GA    38 (34.5%)   37 (33.6%) 
AA    12 (10.9%)   9 (8.2%) 
χ2=0.57; P-value=0.75. 
 
Alleles    MS cases (n=110) Control cases (n=110) 
G    158 (71.8%)   165 (75%) 
A    62 (28.2%)   55 (25%) 
χ2=0.57; P-value=0.45. 
 
a Hardy–Weinberg equilibrium P=0.17. 
b Hardy–Weinberg equilibrium P=0.27. 
 
3. Results 
The genotype and allele frequencies for all the two variants are shown in Table 1 and Table 2. 
All genotypes for the case-control association studies conformed to Hardy–Weinberg 
equilibrium (HWE) expectations (P > 0.05) in both case and control groups. The allele and 
genotype frequencies for both the PvuII (P = 0.50 and P = 0.63, respectively) and Btg1 
(P = 0.45 and P = 0.75, respectively) variants, showed no significant difference between the 
MS population and the control population. In our investigation, we showed no association of 
these ESR1 markers with RR-MS, PP-MS and SP-MS.  
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4. Discussion 
The aim of this study was to investigate two sequence polymorphisms in the ESR1 gene, 
PvuII and Btg1, for their involvement in MS susceptibility within an Australian cohort. For 
both markers, genotypes were investigated in 110 MS patients and 110 matched controls. In 
this present study, we report no association of these markers with MS. Both genotype and 
allele frequency distributions for both ESR1 markers showed no significant differences 
between the MS and control populations. In our investigation, we also showed no association 
of these ESR1 markers with RR-MS, PP-MS and SP-MS. Although these results were clearly 
non-significant, the cohort of MS individuals used in this study is of moderate size and further 
investigation with larger cohorts should be considered to determine more specifically whether 
ESR variants have a low or moderate effect on disease susceptibility. 
In MS, women are more affected than men with a ratio of 3:2 and this female 
prevalence is also encountered in the experimental allergic encephalomyelitis (EAE) MS 
animal model [11]. A striking point found in MS and observed as well in rheumatoid arthritis 
(RA) is the reduction of disease linked symptomatology during pregnancy [12]. In contrast, 
after parturition, flares of the disease are recorded in affected women [2]. Proinflammatory 
cytokines induce local inflammation in the CNS leading to CNS demyelination. Such 
cytokines can be modulated in expression by steroid hormones with direct immuno-
suppression observed in EAE MS like animal models [13]. Estrogen receptor polymorphic 
variants have been previously investigated in MS but with conflicting results. Two studies 
gave positive association of the ESR1 PvuII polymorphism with MS [14] and [15] while a 
more recent study gave negative association findings for the ESR1 PvuII polymorphism [16]. 
In this present report we show no association of the PvuII marker in the ESR1 gene with MS 
in an Australian population reinforcing previously negative results by Savettieri et al. [16]. 
However, we cannot exclude the possibility that other markers within ESR1 could be 
involved in MS susceptibility. Indeed, recent evidence suggests that estrogens could influence 
the gender difference observed in MS and other neurological disorders [17]. Studies on 
animal models have shown estradiol (E2) dose dependent inhibition of clinical signs of EAE 
when E2 was given a week before EAE induction [18] and [19]. Also of interest, several 
positive association results have been found between estrogen receptor variants and other 
autoimmune disorders including lupus and rheumatoid arthritis [20] and [21] as well as with 
the Parkinson neurodegenerative disease [22]. In addition, an association has also been found 
between the PvuII ESR1 polymorphism and the HLA DR2 allele [15] and a recent Japanese 
study found an independent positive association of the ESR1 PvuII T allele with HLA-
DRB1 1511 allele, an allele associated with MS development [23].  
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